EIKONOKLASTES THERAPEUTICS, INC. — SEC Form D Filing
EIKONOKLASTES THERAPEUTICS, INC. filed an SEC Form D on October 5, 2026, reporting $16.06M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 5, 2026
- Amount reported
- $16.06M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://eikonoklastes.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffer from severe neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), which cause progressive muscle degeneration, cognitive loss, and eventual death. These conditions have high unmet clinical needs with few effective treatment options beyond supportive care.
Solution
The company is developing ET-101 (SYNCAV1), a first-in-class, disease-modifying gene therapy that uses AAV9 to deliver additional copies of the Caveolin-1 gene to neurons. This therapy aims to overexpress Caveolin-1 to induce neuroprotection and neuroplasticity, helping nerve cells compensate for damage and improving functional ability in neurodegenerative diseases.
Verdict
This cleared because investors were funding a high-risk, high-reward bet on a novel gene therapy mechanism for severe neurodegenerative diseases, not because a clear path to market or a robust competitive moat was articulated. They implicitly bet on the scientific team's ability to validate the Caveolin-1 overexpression hypothesis in human trials, hoping for a breakthrough in an area with desperate unmet need. The limited upside stemmed from the binary nature of drug development success and the extensive capital requirements before any commercial viability.
Source: SEC EDGAR Form D filing